Advantages of Sustained-Release Therapy With Acetazolamide in Glaucoma*

Comparison of the effect of acetazolamide tablets and sustets on diurnal intraocular pressure in patients with chronic simple glaucoma.

“…This does gave a plasma value of 4-5 mg/l, which is calculated to give 99% inhibition of carbonic anhydrase in the ciliary epithelium. In our study the mean plasma concentration on acetazolamide tablets was 8-6 mg/l (SD 2-8) and on Sustets was 9X7 mg/l (SD [3][4][5][6][7][8]. This could account for the satisfactory control of IOP in this group of patients, but the topical treatment may have had an overriding influence.…”

“…In our study the mean IOP off acetazola mide was 25-1 mmHg (SD IF4). It is interestin to observe that the mean IOP on both prepare tions was similar -18 mmHg (SD 1-8) for tablet and 18-1 mmHg (SD [1][2][3][4][5][6] for Sustets. Since th majority of patients were on an evening dose c acetazolamide only, once daily treatment wouli appear to be adequate to control IOP.…”

Untitled

“…It was reported that the incidence of side effects were much lower and the tolerance was much greater with acetazolamide sustained release capsule when compared with the conventional acetazolamide tablet 4 .…”